Literature DB >> 22566376

Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment.

Jürg P F Nüesch1, Jeannine Lacroix, Antonio Marchini, Jean Rommelaere.   

Abstract

Rodent parvoviruses (PV) are recognized for their intrinsic oncotropism and oncolytic activity, which contribute to their natural oncosuppressive effects. Although PV uptake occurs in most host cells, some of the subsequent steps leading to expression and amplification of the viral genome and production of progeny particles are upregulated in malignantly transformed cells. By usurping cellular processes such as DNA replication, DNA damage response, and gene expression, and/or by interfering with cellular signaling cascades involved in cytoskeleton dynamics, vesicular integrity, cell survival, and death, PVs can induce cytostasis and cytotoxicity. Although productive PV infections normally culminate in cytolysis, virus spread to neighboring cells and secondary rounds of infection, even abortive infection or the sole expression of the PV nonstructural protein NS1, is sufficient to cause significant tumor cell death, either directly or indirectly (through activation of host immune responses). This review highlights the molecular pathways involved in tumor cell targeting by PVs and in PV-induced cell death. It concludes with a discussion of the relevance of these pathways to the application of PVs in cancer therapy, linking basic knowledge of PV-host cell interactions to preclinical assessment of PV oncosuppression. ©2012 AACR.

Entities:  

Mesh:

Year:  2012        PMID: 22566376     DOI: 10.1158/1078-0432.CCR-11-2325

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  41 in total

1.  Cell cycle S phase markers are expressed in cerebral neuron nuclei of cats infected by the Feline Panleukopenia Virus.

Authors:  Luc Poncelet; Mutien Garigliany; Kunie Ando; Mathieu Franssen; Daniel Desmecht; Jean-Pierre Brion
Journal:  Cell Cycle       Date:  2016-11-10       Impact factor: 4.534

2.  Generation of an adenovirus-parvovirus chimera with enhanced oncolytic potential.

Authors:  Nazim El-Andaloussi; Serena Bonifati; Johanna K Kaufmann; Laurent Mailly; Laurent Daeffler; François Deryckère; Dirk M Nettelbeck; Jean Rommelaere; Antonio Marchini
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

3.  Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells.

Authors:  Justin C Paglino; Wells Andres; Anthony N van den Pol
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 4.  New viruses for cancer therapy: meeting clinical needs.

Authors:  Tanner S Miest; Roberto Cattaneo
Journal:  Nat Rev Microbiol       Date:  2013-12-02       Impact factor: 60.633

5.  Sialoglycovirology of Lectins: Sialyl Glycan Binding of Enveloped and Non-enveloped Viruses.

Authors:  Nongluk Sriwilaijaroen; Yasuo Suzuki
Journal:  Methods Mol Biol       Date:  2020

Review 6.  Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses.

Authors:  Julia Fakhiri; Dirk Grimm
Journal:  Mol Ther       Date:  2021-04-05       Impact factor: 11.454

Review 7.  Viral Proteins as Emerging Cancer Therapeutics.

Authors:  Ekta Manocha; Arnaldo Caruso; Francesca Caccuri
Journal:  Cancers (Basel)       Date:  2021-05-03       Impact factor: 6.639

8.  Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry.

Authors:  Amit Kulkarni; Tiago Ferreira; Clemens Bretscher; Annabel Grewenig; Nazim El-Andaloussi; Serena Bonifati; Tiina Marttila; Valérie Palissot; Jubayer A Hossain; Francisco Azuaje; Hrvoje Miletic; Lars A R Ystaas; Anna Golebiewska; Simone P Niclou; Ralf Roeth; Beate Niesler; Amélie Weiss; Laurent Brino; Antonio Marchini
Journal:  Nat Commun       Date:  2021-06-22       Impact factor: 14.919

9.  Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer.

Authors:  Matthias Neulinger-Muñoz; Dominik Schaack; Svetlana P Grekova; Andrea S Bauer; Thomas Giese; Gabriel A Salg; Elisa Espinet; Barbara Leuchs; Anette Heller; Jürg P F Nüesch; Miriam Schenk; Michael Volkmar; Nathalia A Giese
Journal:  Viruses       Date:  2021-05-28       Impact factor: 5.048

10.  TLR-9 contributes to the antiviral innate immune sensing of rodent parvoviruses MVMp and H-1PV by normal human immune cells.

Authors:  Zahari Raykov; Svitlana P Grekova; Rita Hörlein; Barbara Leuchs; Thomas Giese; Nathalia A Giese; Jean Rommelaere; Rainer Zawatzky; Laurent Daeffler
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.